Company Filing History:
Years Active: 2021
Title: Innovations by Inventor Nelson Guerreiro
Introduction
Nelson Guerreiro is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of two patents to his name, Guerreiro's work focuses on enhancing the efficacy and safety of cancer therapies.
Latest Patents
Guerreiro's latest patents include groundbreaking inventions aimed at improving cancer treatment. The first patent, titled "Dose and regimen for HDM2-p53 interaction inhibitors," relates to HDM2-p53 interaction inhibitors for use in cancer treatment. This invention emphasizes a high dose intermittent dosing regimen, particularly involving the HDM2-p53 interaction inhibitor HDM20I and a specific dosing regimen of di, d8 over a four-week cycle. The second patent, "GDF-15 as a haematological toxicity biomarker," discusses the use of GDF-15 as a safety biomarker to assess the toxicological effects of Mdm2 inhibitors. This patent outlines methods for predicting the likelihood of developing thrombocytopenia in patients undergoing treatment with Mdm2 inhibitors.
Career Highlights
Nelson Guerreiro is currently employed at Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in the pharmaceutical industry, particularly in oncology. His contributions have been instrumental in advancing cancer treatment methodologies.
Collaborations
Guerreiro collaborates with esteemed colleagues such as Christophe Meille and Jens Wuerthner. These partnerships enhance the research and development efforts within his field, fostering innovation and progress in cancer therapies.
Conclusion
Nelson Guerreiro's contributions to cancer treatment through his patents reflect his dedication to improving patient outcomes. His innovative work at Novartis AG continues to pave the way for advancements in oncology.